Nonalcoholic fatty liver disease: lifestyle and quality of life
- PMID: 34854066
- DOI: 10.1007/s42000-021-00339-6
Nonalcoholic fatty liver disease: lifestyle and quality of life
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a metabolic disorder whose current rapidly expanding prevalence is causing it to develop into a major global health concern. NAFLD is closely linked to the modern, unhealthy lifestyle. The Western diet, characterized by excessive energy intake, frequent consumption of red meat, processed meat and foods, soft drinks, and sugar-sweetened beverages (SSBs), irregular meal distribution throughout the day, and unhealthy ways of cooking, predisposes to development of NAFLD. Low levels of physical activity and prolonged sedentary time are additional lifestyle risk factors for NAFLD. Given the present lack of effective pharmacological treatment, lifestyle modifications are regarded as the cornerstone of NAFLD management. Reducing daily calorie intake together with following the Mediterranean diet (MD) is an increasingly accepted approach. Furthermore, increasing the level of physical activity and limiting sedentary behavior are additional measures proposed to improve the outcomes of the disease. Apart from being affected by lifestyle, NAFLD may also affect patients' quality of life (QoL), mostly in the domain of physical function. In this regard, while the early and more benign form of the disease, i.e., simple hepatic steatosis, may not affect QoL, there is evidence, though conflicting, of the impact of nonalcoholic steatohepatitis (NASH) on this index, with, however, most studies showing that QoL is consistently affected in advanced disease, i.e., hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. Considering all the above, appropriate management of lifestyle is likely to attenuate the severity of the disease and improve the QoL of NAFLD patients.
Keywords: Diet; Lifestyle; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Physical activity; Quality of life.
© 2021. Hellenic Endocrine Society.
Similar articles
-
[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].Yakugaku Zasshi. 2019;139(9):1147-1153. doi: 10.1248/yakushi.19-00011-1. Yakugaku Zasshi. 2019. PMID: 31474630 Review. Japanese.
-
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263. World J Gastroenterol. 2017. PMID: 29307986 Free PMC article. Review.
-
Impact of lifestyle interventions on pathogenesis of nonalcoholic fatty liver disease.World J Gastroenterol. 2024 May 28;30(20):2633-2637. doi: 10.3748/wjg.v30.i20.2633. World J Gastroenterol. 2024. PMID: 38855152 Free PMC article.
-
Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.Z Gastroenterol. 2019 Apr;57(4):508-517. doi: 10.1055/a-0784-8827. Epub 2019 Apr 9. Z Gastroenterol. 2019. PMID: 30965381 Review. English.
-
Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.Am J Physiol Gastrointest Liver Physiol. 2018 Sep 1;315(3):G329-G338. doi: 10.1152/ajpgi.00044.2018. Epub 2018 Jun 7. Am J Physiol Gastrointest Liver Physiol. 2018. PMID: 29878845
Cited by
-
Circulating Ferritin in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.J Clin Exp Hepatol. 2024 May-Jun;14(3):101353. doi: 10.1016/j.jceh.2024.101353. Epub 2024 Feb 2. J Clin Exp Hepatol. 2024. PMID: 38435724 Free PMC article. Review.
-
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease.Ther Clin Risk Manag. 2023 Jan 22;19:77-96. doi: 10.2147/TCRM.S352008. eCollection 2023. Ther Clin Risk Manag. 2023. PMID: 36713291 Free PMC article. Review.
-
Optimizing lifestyle profiles is potential for preventing nonalcoholic fatty liver disease and enhancing its survival.Sci Rep. 2024 Mar 6;14(1):5516. doi: 10.1038/s41598-024-55566-9. Sci Rep. 2024. PMID: 38448563 Free PMC article.
-
Hepatic steatosis induced by nicotine plus Coca-Cola™ is prevented by nicotinamide riboside (NR).Front Endocrinol (Lausanne). 2024 May 2;15:1282231. doi: 10.3389/fendo.2024.1282231. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38756999 Free PMC article.
-
Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life.Hepatol Commun. 2022 Oct;6(10):2623-2633. doi: 10.1002/hep4.2044. Epub 2022 Jul 28. Hepatol Commun. 2022. PMID: 35903833 Free PMC article.
References
-
- Makri E, Goulas A, Polyzos SA (2021) Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res 52:25–37. https://doi.org/10.1016/j.arcmed.2020.11.010 - DOI - PubMed
-
- Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES et al (2017) The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement Metab 71:17–32. https://doi.org/10.1016/j.metabol.2017.02.014 - DOI
-
- (2016) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388–402. https://doi.org/10.1016/j.jhep.2015.11.004
-
- Polyzos SA, Kountouras J, Zavos C, Deretzi G (2012) Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 46:272–284. https://doi.org/10.1097/MCG.0b013e31824587e0 - DOI - PubMed
-
- Hydes T, Alam U, Cuthbertson DJ (2021) The impact of macronutrient intake on non-alcoholic fatty liver disease (NAFLD): too much fat, too much carbohydrate, or just too many calories? Front Nutr 8:640557. https://doi.org/10.3389/fnut.2021.640557 - DOI - PubMed - PMC
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical